Characterization of tumor vaccines during product development

Vaccine

Volumn 19, Issue 6, 2000, Pages

  Razzaque, Abdur ^a   Dye, Earl ^a   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Product development; Regulatory issues; Tumor vaccines

Indexed keywords

ANTIGEN; CYTOKINE; GROWTH FACTOR; LIPOSOME; PEPTIDE; PLASMID VECTOR; TUMOR ANTIGEN; TUMOR VACCINE; VIRUS VECTOR;

ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CELL LYSATE; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DNA MODIFICATION; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LAW; LICENSING; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR CELL; TUMOR REGRESSION;

EID: 0034623663     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00251-6     Document Type: Note

References (26)

1. Autologous hapten-modifiedmelanoma cell vaccine as postsurgical adjuvant treatment after resection of nodal metastases
2. Active immunotherapy with allogeneic tumor cell vaccine: present status
3. Systemic T cell adoptic immunotherapy of malignant gliomas
4. Paracrine cytokine adjuvants in cancer immunotherapy
5. Induction of antitumor activity by immunization with fusions of dendritic carcinoma cells
6. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
7. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
8. Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells
9. Dendritic cells acquire antigen from apoptotic cells and induce class1-restricted CTLs
10. Ganglioside vaccines with emphasis on GM2
11. Cancer vaccines based on the identification of genes encoding cancer regression antigens
12. Immunotherapy with autologous tumor-derived heat shock protein preparations
13. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
14. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
15. Tumor prevention and rejection with recombinant vaccinia
16. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector
17. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector
18. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen
19. A replication-defective human adenovirus recombinant serves as highly efficacious vaccine
20. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
21. Biologic effects and potential clinical applications of Flt3 ligand